Turning Point Therapeutics TPTX shares are trading higher on Wednesday.
Wells Fargo has maintained its Overweight rating on the stock and raised its price target from $62 to $76 per share.
Turning Point Therapeutics is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies.
Turning Point Therapeutics shares were up 8.08% at $56.99 at time of publication on Wednesday. The stock has a 52-week high of $67.54 and a 52-week low of $29.47.
Related Links:
Volunteers Begin Testing Moderna Coronavirus Vaccine
Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
